Tolvaptan
- Generic Name
- Tolvaptan
- Brand Names
- Jinarc, Jynarque 45/15 Carton, Samsca, Tolvaptan Accord, Xeljanz
- Drug Type
- Small Molecule
- Chemical Formula
- C26H25ClN2O3
- CAS Number
- 150683-30-0
- Unique Ingredient Identifier
- 1E2497LPNY
- Background
Tolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
- Indication
Treatment of symptomatic and resistant to fluid restriction euvolemic or hypervolemic hyponatremia associated with congestive heart failure, SIADH, and cirrhosis.
- Associated Conditions
- Autosomal Dominant Polycystic Kidney Disease （ADPKD), Symptomatic euvolemic Hyponatremia, Symptomatic hypervolemic Hyponatremia
- Associated Therapies
- -
An Extension Follow-up Trial to Evaluate the Long-term Safety of Children and Adolescent Participants With Euvolemic or Hypervolemic Hyponatremia
- First Posted Date
- 2013-12-24
- Last Posted Date
- 2020-04-17
- Target Recruit Count
- 3
- Registration Number
- NCT02020278
Study of the Safety and Effectiveness of SAMSCA® (Tolvaptan) in Children and Adolescents With Euvolemic or Hypervolemic Hyponatremia
- First Posted Date
- 2013-12-17
- Last Posted Date
- 2018-09-26
- Target Recruit Count
- 9
- Registration Number
- NCT02012959
A PK Study of 3 Dosages of Tolvaptan in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH)
- Conditions
- Interventions
- First Posted Date
- 2013-12-12
- Last Posted Date
- 2016-05-16
- Target Recruit Count
- 30
- Registration Number
- NCT02009878
- Locations
- 🇪🇸
Hospital Universitario Clinico San Carlos, Madrid, Spain
🇩🇪Medizinische Klinik im Klinikum Hannover, Hannover, Niedersachsen, Germany
🇨🇿Vseobecna fakultni nemocnice V Praze, Praha, Czech Republic
Open-Label Extension Study Of Tofacitinib In Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2013-11-05
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 686
- Registration Number
- NCT01976364
- Locations
- 🇺🇸
Altoona Center for Clinical Research, Duncansville, Pennsylvania, United States
🇧🇪ZNA Jan Palfijn, Merksem, Belgium
🇧🇷Hospital de Clinicas de Porto Alegre (HCPA) / UFRGS, Porto Alegre, RS, Brazil
Effects of Tolvaptan in Healthy Adults
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2016-09-28
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 17
- Registration Number
- NCT01973140
- Locations
- 🇺🇸
Clinical Research Unit Northwestern Memorial Hospital, Chicago, Illinois, United States
Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia
- First Posted Date
- 2013-07-02
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 2
- Registration Number
- NCT01890694
- Locations
- 🇺🇸
NYU Langone Medical Center, New York, New York, United States
Tofacitinib In Psoriatic Arthritis Subjects With Inadequate Response to TNF Inhibitors
- First Posted Date
- 2013-06-20
- Last Posted Date
- 2017-09-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 395
- Registration Number
- NCT01882439
- Locations
- 🇺🇸
St. Luke's Intermountain Research Center, Boise, Idaho, United States
🇺🇸Clinical Pharmacology Study Group, Worcester, Massachusetts, United States
🇺🇸University Hospitals Case Medical Center, Cleveland, Ohio, United States
Tolvaptan/Ultrafiltration in the Treatment of Acute Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2013-05-29
- Last Posted Date
- 2016-01-28
- Lead Sponsor
- The Christ Hospital
- Target Recruit Count
- 45
- Registration Number
- NCT01863511
- Locations
- 🇺🇸
The Christ Hospital, Cincinnati, Ohio, United States
Efficacy and Safety of Tolvaptan in Cirrhotic Patients With Hyponatremia
- Conditions
- Interventions
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2015-07-28
- Lead Sponsor
- Beijing Friendship Hospital
- Target Recruit Count
- 98
- Registration Number
- NCT01850940
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
🇨🇳Guangdong General Hospital, Guangdong, Guangdong, China
🇨🇳Beijing Ditan Hospital, Beijing, Beijing, China
A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494
- Conditions
- Interventions
- First Posted Date
- 2012-12-05
- Last Posted Date
- 2017-11-20
- Lead Sponsor
- AbbVie (prior sponsor, Abbott)
- Target Recruit Count
- 67
- Registration Number
- NCT01741493
- Locations
- 🇺🇸
Site Reference ID/Investigator# 95815, Duncansville, Pennsylvania, United States
🇺🇸Site Reference ID/Investigator# 95817, Miami, Florida, United States
🇺🇸Site Reference ID/Investigator# 95816, Cincinnati, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.